Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 1/5 criteria met.
- ❌ Price trend failed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -66.67%
Price change 2019 → 2020: 320.00%
Price change 2020 → 2021: -47.62%
Price change 2021 → 2022: -96.80%
Price change 2022 → 2023: -84.43%
Price change 2023 → 2024: 78.83%
Price change 2024 → 2025: -21.22%
Price change 2025 → 2026: -42.49%
Price change 2026 (year to date): -45.05%
Financial growth
Revenue CAGR (8 years): -34.90%
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.03
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -3.63
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 50.45% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="IBIO" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| iBio, Inc. | – | 0.24 | – | 🔒 |
| FamiCord AG | – | 3.30 | +11.6 % | – |
| Fermentalg | – | 0.20 | +38.5 % | – |
| Klea Holding | 15.8 | 0.20 | +5.2 % | – |
| DocCheck AG | 11.2 | 0.10 | +8.9 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by iBio, Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 1.6 m | -16.4 m | -1,003.6 % | n/a |
| 2021 | 2.4 m | -23.2 m | -978.8 % | +44.7 % |
| 2022 | 1.9 m | -50.4 m | -2,674.7 % | -20.5 % |
| 2024 | 225,000 | -24.9 m | -11,069.8 % | -88.1 % |
| 2025 | 400,000 | -18.4 m | -4,594.2 % | +77.8 % |
| 2026 | 100,000 | -33.0 m | -33,044.0 % | -75.0 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by iBio, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash and investments | 33.5 m | 7.3 m | 14.2 m | 8.6 m | 88.0 m |
| Total Debt | 25.8 m | 17.1 m | 4.5 m | 3.5 m | 2.2 m |
| Net Debt | 3.1 m | 9.7 m | -9.8 m | -5.1 m | -54.2 m |
| Equity | 63.5 m | 15.4 m | 21.3 m | 14.9 m | 85.7 m |
| Total assets | 99.4 m | 41.2 m | 28.7 m | 23.2 m | 99.1 m |
| Operating cash flow | -37.8 m | -30.4 m | -18.6 m | -15.3 m | -23.2 m |
| Investments (capex) | 11.6 m | 5.7 m | 210,000 | 16,000 | 578,000 |
| Free cash-flow | -45.1 m | -36.2 m | -18.8 m | -15.3 m | -23.8 m |
| Share buybacks | 0 | 39,000 | 7,000 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.
Dividends and earnings
iBio, Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 10/11/2026 | -0.05 | -0.07 | n/a |
| 28/08/2026 | -0.04 | -0.07 | n/a |
| 12/05/2026 | -0.07 | -0.06 | n/a |
| 10/02/2026 | -0.09 | -0.08 | n/a |
| 12/11/2025 | -0.11 | -0.07 | n/a |
| 05/09/2025 | -0.31 | -0.39 | n/a |
Stock splits
| Date | Operation |
|---|---|
| 29/11/2023 | reverse split: 1 share for 20 |
| 10/10/2022 | reverse split: 1 share for 25 |
| 11/06/2018 | reverse split: 1 share for 10 |
Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about iBio, Inc.
What is the iBio, Inc. share price?
Latest recorded price: 0.732 USD on 13/11/2026, for a market cap of 51.6 m USD.
What is the revenue of iBio, Inc.?
100,000 USD for fiscal year 2026, with net income of -33.0 m USD (net margin -33,044.0 %).
Is iBio, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US4510337086).
How many employees does iBio, Inc. have?
16 full-time employees according to the latest published profile.
Who runs iBio, Inc.?
Martin B. Brenner is the company's chief executive.